Search Result

Results for "

HLA-A

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AIM2 (1) Amino Acid Derivatives (2) Apoptosis (1) CMV (2) Complement System (1) DNA/RNA Synthesis (1) EBV (6) EGFR (2) HCV (1) HIV (1) HPV (3) IFNAR (2) Influenza Virus (1) Interleukin Related (1) Melanocortin Receptor (1) MHC (11) Small Interfering RNA (siRNA) (1) Survivin (1) TNF Receptor (2) Tyrosinase (2)
By Research Areas:	Cancer (25) Infection (7) Inflammation/Immunology (11) Metabolic Disease (1)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

169

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1780

CEF20	CMV	Infection
CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P990832

Anti-MHC Class I Antibody (W6/32)	MHC	Inflammation/Immunology
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human MHC Class I. Anti-MHC Class I Antibody (W6/32) reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. Anti-MHC Class I Antibody (W6/32) increases adherence of monocytes to human endothelial cells. Anti-MHC Class I Antibody (W6/32) can be used for the research of immunology .

HY-P1780A

CEF20 TFA	CMV	Infection
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P1778A

HPV16 E7 (86-93) TFA	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .

HY-P10664

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Tyrosinase	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-RS06196

HLA-A Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HLA-A Human Pre-designed siRNA Set A contains three designed siRNAs for HLA-A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HLA-A Human Pre-designed siRNA Set A HLA-A Human Pre-designed siRNA Set A

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10994

Eps8 peptide 327 Eps8(327-335)	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-P11089

TP53 neoepitope	MHC	Cancer
TP53 neoepitope is a high-affinity antigenic peptide targeting *HLA-A*. TP53 neoepitope can triggers CD8 ⁺ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .

HY-P1700

BCMA72-80	TNF Receptor	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro*. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P11379

ELTLGEFLKL	Survivin MHC	Inflammation/Immunology Cancer
ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of **HLA-A0201***. ELTLGEFLKL can be used in the research of tumor immunotherapy .

HY-P1757

HIV p17 Gag (77-85)	HIV	Infection
HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P991247

*Anti-HLA-A2 (Hu8F4)*	MHC	Cancer
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting *HLA-A2. Anti-HLA*-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P5294

YLLEMLWRL	EBV	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

HY-P5478

Influenza virus PA (46-54)	DNA/RNA Synthesis Influenza Virus	Others
Influenza virus PA (46-54) is a biological active peptide. (HLA-A*0201 restricted epitope from influenza virus RNA polymerase subunit, PA (46-54).)

HY-P5482

Epstein-barr virus BRLF1 (134-142)	EBV	Others
Epstein-barr virus BRLF1 (134-142) is a biological active peptide. (HLA-A11 restricted epitope from Epstein-Barr Virus BRLF1 (134-142).)

HY-P991787

*Anti-HLA-A2 Antibody (BB7.2)*	MHC	Inflammation/Immunology
Anti-HLA-A2 Antibody (BB7.2) reacts with the alpha subunit of the human leukocyte antigen-A2 (HLA-A2). Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .

HY-P11434

Adipophilin-derived peptide	MHC	Cancer
Adipophilin-derived peptide is a peptide derived from Adipophilin. Adipophilin-derived peptide binds to **HLA-A0201***. Adipophilin-derived peptide can be used in cancer research .

HY-P11383

AIM2-derived decapeptide	AIM2 MHC	Cancer
AIM2-derived decapeptide is an AIM2-derived decapeptide and *HLA-A1*-restricted T-cell epitope. AIM2-derived decapeptide can be used in the research of melanoma .

HY-P11084A

WT1 126-134 peptide acetate	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .

HY-P11713

EBNA3B 399-408	EBV MHC	Infection Cancer
EBNA3B 399-408 is an immunodominant *HLA-A11*-restricted cytotoxic T-lymphocyte epitope in EBNA3B. EBNA3B 399-408 can be used in the research of EBV infection, empyema-associated lymphoma, and nasal natural killer cell lymphoma .

HY-P11714

EBNA3 246-254	EBV MHC	Infection Cancer
EBNA3 246-254 (RYSIFFDYM) is an EBV peptide. EBNA3 246-254 is submitted by *HLA-A24. EBNA3 246-254 is amplified in vitro, followed by HLA* multimer staining to measure EBV-specific CTLs. EBNA3 246-254 can be used for the research of lung cancer .

HY-106187B

MART-1 (27-35) (human) TFA		Cancer
MART-1 (27-35) (human) (TFA) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) (TFA) can be used in studies related to melanoma .

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

Cat. No.	Product Name	Target	Research Area

HY-P0277

Carcinoembryonic antigen peptide 1 CEA peptide	Peptides	Cancer
Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A*0201-restricted CTL epitope that can be used for the study of CTL-mediated epithelial-derived cancers .

HY-P1780

CEF20	CMV	Infection
CEF20 is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P5470

LMP2A (426-434)	EBV IFNAR	Inflammation/Immunology
LMP2A (426-434) is a HLA-A2-restricted cytotoxic T lymphocyte (CTL) epitope of Epstein-Barr virus (EBV) latent membrane protein 2A (LMP2A). LMP2A (426-434) can trigger an immune response in individuals expressing different HLA-A02 subtypes (A02:01, A02:03, A02:06 and A02:07). LMP2A (426-434) can induce a strong IFN-γ* secretion response, stimulating the production of a high proportion of CD8 ⁺ IFN-γ ⁺ T cells. LMP2A (426-434) induces specific CTLs to effectively kill target cells expressing LMP2A. LMP2A (426-434) can be used to study EBV-related malignant tumors (such as Hodgkin's disease and nasopharyngeal carcinoma) .

HY-P10493

NY-ESO-1 (157-165) peptide	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P1780A

CEF20 TFA	CMV	Infection
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503).

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P1778A

HPV16 E7 (86-93) TFA	HPV	Infection
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) TFA is immunogenic in cervical carcinomas .

HY-P10664

EBV EBNA3B (416-424)	EBV	Inflammation/Immunology
EBV EBNA3B (416-424) is an HLA-A11-restricted peptide antigen derived from EBV EBNA3B protein .

HY-P1919

[Asp371]-Tyrosinase (369-377), human	Tyrosinase	Cancer
Tyrosinase 369-377, human is a HLA-A2.1-restricted epitope derived from tyrosinase, has been used to develop tumor-targeted vaccines with mixed efficacy .

HY-P11084

WT1 126-134 peptide	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide can be used as a vaccine for T cells or as a target for antibodies .

HY-P1855

HER2/neu (654-662) GP2	EGFR	Cancer
HER2/neu (654-662) GP2 is a nine amino acid peptide derived from the human epidermal growth factor receptor 2 (HER2/nue, 654–662), induces HLA-A2-restricted cytotoxic T lymphocytes (CTL) reactive to various epithelial cancers .

HY-P10493A

NY-ESO-1 (157-165) peptide TFA	Amino Acid Derivatives	Cancer
NY-ESO-1 (157-165) peptide (TFA) is a peptide fragment from NY-ESO-1 protein. NY-ESO-1 (157-165) peptide (TFA) can activate the immune system, especially for HLA-A2 positive individuals, it can be recognized by CD8+ T cells, thus triggering an immune response. NY-ESO-1 (157-165) peptide (TFA) is expressed in a variety of tumors and can be used as a target for tumor immunotherapy .

HY-P10994

Eps8 peptide 327 Eps8(327-335)	EGFR IFNAR Interleukin Related TNF Receptor Complement System Apoptosis	Inflammation/Immunology Cancer
Eps8 peptide 327 is an HLA-A2402-restricted peptide antigen derived from Eps8 protein. Eps8 peptide 327 has potent antitumor activity with significant cytotoxicity. Eps8 peptide 327 effectively inhibits cancer cells proliferation, induces apoptosis* and disrupts EGFR signal pathway by inhibiting downstream signals (such as IL-2, TNF-α and IFN-γ) expression and the Eps8/EGFR interaction. Eps8 peptide 327 significantly inhibits tumor growth in HT-29 xenograft mcie models .

HY-P11089

TP53 neoepitope	MHC	Cancer
TP53 neoepitope is a high-affinity antigenic peptide targeting *HLA-A*. TP53 neoepitope can triggers CD8 ⁺ T cell-mediated killing of TP53-mutant tumor cells. TP53 neoepitope is promising for research of solid tumors harboring TP53 hotspot mutations (e.g., R175H, R273H) .

HY-P1700

BCMA72-80	TNF Receptor	Cancer
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with great affinity to HLA-A2, used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro*. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P11379

ELTLGEFLKL	Survivin MHC	Inflammation/Immunology Cancer
ELTLGEFLKL is a survivin peptide. ELTLGEFLKL shows significant stabilization of **HLA-A0201***. ELTLGEFLKL can be used in the research of tumor immunotherapy .

HY-P1757

HIV p17 Gag (77-85)	HIV	Infection
HIV p17 Gag (77-85) is an HLA-A*0201(A2)-restricted CTL epitope, used in the research of anti-HIV .

HY-P1778

HPV16 E7 (86-93)	HPV	Infection
HPV16 E7 (86-93) is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. HPV16 E7 (86-93) is immunogenic in cervical carcinomas .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P5294

YLLEMLWRL	EBV	Cancer
YLLEMLWRL is an HLA-A2-restricted T cell epitope sequence corresponding to codon 125-133. Among them, YLLEMLWRL sequence is the main mutation site of HLA-A2-restricted CTL epitope sequence .

HY-P5476

Influenza virus NP (44-52)	Peptides	Others
Influenza virus NP (44-52) is a biological active peptide. (HLA-A*01 restricted epitope from influenza virus nucleoprotein (44-52).)

HY-106187

MART-1 (27-35) (human)	Peptides	Inflammation/Immunology
MART-1 (27-35) (human) is an immunogenic epitope recognized by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TIL) .

HY-P5478

Influenza virus PA (46-54)	DNA/RNA Synthesis Influenza Virus	Others
Influenza virus PA (46-54) is a biological active peptide. (HLA-A*0201 restricted epitope from influenza virus RNA polymerase subunit, PA (46-54).)

HY-P5482

Epstein-barr virus BRLF1 (134-142)	EBV	Others
Epstein-barr virus BRLF1 (134-142) is a biological active peptide. (HLA-A11 restricted epitope from Epstein-Barr Virus BRLF1 (134-142).)

HY-P1914

NY-BR-1 p904 (A2)	Peptides	Cancer
NY-BR-1 p904 (A2) is an HLA-A2-restricted NY-BR-1 epitope. T-cell clone specific for NY-BR-1 p904 can recognize breast tumor cells expressing NY-BR-1 .

HY-P2524

MAGE-3 (271-279)	Peptides	Cancer
MAGE-3 (271-279) is a 271-279 residue peptide derived from melanoma antigens encoded by MAGE-3. MAGE-3 is a cytolytic T lymphocyte (CTL)-defined MAGE-3 protein associated with the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is overexpressed in different human tumor types, including malignant melanoma, but not by normal tissues except for testis and placenta .

HY-P5471

Melan-A/MART-1 analog [Leu27]-Melan-A, MART-1 (26-35)	Peptides	Others
Melan-A/MART-1 analog ([Leu27]-Melan-A, MART-1 (26-35)) is a biological active peptide. (This Melan-A (26-35) analog, Leu substituted for Ala at position 27, shows better HLA-A*0201 binding properties as well as better immunogenicity and antigenicity than the natural Melan-A (26-35).Pyroglutamyl (pGlu) peptides may spontaneously form when either Glutamine (Q) or Glutamic acid (E) is located at the sequence N-terminus. The conversion of Q or E to pGlu is a natural occurrence and in general it is believed that the hydrophobic γ-lactam ring of pGlu may play a role in peptide stability against gastrointestinal proteases. Pyroglutamyl peptides are therefore considered a normal subset of such peptides and are included as part of the peptide purity during HPLC analysis.)

HY-P4667

VLHDDLLEA	Peptides	Metabolic Disease
VLHDDLLEA is a peptide that can be isolated from the MHC complex HLA-A0201 molecule. VLHDDLLEA can be recognized by HLA-A0201-restricted cytotoxic T cells (CTLs). VLHDDLLEA can be used for research on graft versus host disease (GvHD) .

HY-P5477

Influenza virus NP (266-274)	Peptides	Others
Influenza virus NP (266-274) is a biological active peptide. (HLA-A*03 restricted epitope from influenza virus nucleoprotein (265-274).)

HY-P11434

Adipophilin-derived peptide	MHC	Cancer
Adipophilin-derived peptide is a peptide derived from Adipophilin. Adipophilin-derived peptide binds to **HLA-A0201***. Adipophilin-derived peptide can be used in cancer research .

HY-P11426

gp100 (17-25)	Peptides	Cancer
gp100 (17-25) is an immunogenic peptide. gp100 (17-25) can generate tumor-specific HLA-A3-restricted T lymphocytes. gp100 (17-25) can be used for melanoma research .

HY-P11383

AIM2-derived decapeptide	AIM2 MHC	Cancer
AIM2-derived decapeptide is an AIM2-derived decapeptide and *HLA-A1*-restricted T-cell epitope. AIM2-derived decapeptide can be used in the research of melanoma .

HY-P11084A

WT1 126-134 peptide acetate	MHC	Inflammation/Immunology Cancer
WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein (WT1) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity (K_d = 0.2 nM) with the humanized monoclonal antibody (IgG1). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies .

HY-P11713

EBNA3B 399-408	EBV MHC	Infection Cancer
EBNA3B 399-408 is an immunodominant *HLA-A11*-restricted cytotoxic T-lymphocyte epitope in EBNA3B. EBNA3B 399-408 can be used in the research of EBV infection, empyema-associated lymphoma, and nasal natural killer cell lymphoma .

HY-P11714

EBNA3 246-254	EBV MHC	Infection Cancer
EBNA3 246-254 (RYSIFFDYM) is an EBV peptide. EBNA3 246-254 is submitted by *HLA-A24. EBNA3 246-254 is amplified in vitro, followed by HLA* multimer staining to measure EBV-specific CTLs. EBNA3 246-254 can be used for the research of lung cancer .

HY-106187B

MART-1 (27-35) (human) TFA		Cancer
MART-1 (27-35) (human) (TFA) is the amino acid fragment spanning positions 27 to 35 of the MART-1 protein, and it represents an immunogenic epitope recognizable by HLA-A2-restricted melanoma-specific tumor-infiltrating lymphocytes (TILs). MART-1 (27-35) (human) (TFA) can be used in studies related to melanoma .

HY-P11129

MAGE-A4 (286-294)	Peptides	Cancer
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-A02 with an affinity of 560.08 nM and an IC₅₀* of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy .

HY-P11280A

PRAME peptide (425-433) acetate	Melanocortin Receptor	Cancer
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma .

Cat. No.	Product Name	Target	Research Area	Image

HY-P990832

Anti-MHC Class I Antibody (W6/32)	MHC	Inflammation/Immunology
Anti-MHC Class I Antibody (W6/32) is a kind of mouse IgG2a κ chimeric antibody inhibitor, targeting to human MHC Class I. Anti-MHC Class I Antibody (W6/32) reacts with the human major histocompatibility complex (MHC) class I, HLA-A, B, and C. Anti-MHC Class I Antibody (W6/32) increases adherence of monocytes to human endothelial cells. Anti-MHC Class I Antibody (W6/32) can be used for the research of immunology .

HY-P991247

*Anti-HLA-A2 (Hu8F4)*	MHC	Cancer
Anti-HLA-A2 (Hu8F4) is a human monoclonal antibody (mAb) targeting *HLA-A2. Anti-HLA*-A2 (Hu8F4) can be used in Acute myeloid leukaemia research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991787

*Anti-HLA-A2 Antibody (BB7.2)*	MHC	Inflammation/Immunology
Anti-HLA-A2 Antibody (BB7.2) reacts with the alpha subunit of the human leukocyte antigen-A2 (HLA-A2). Recommend Isotype Controls: Mouse IgG2b kappa, Isotype Control (HY-P99982) .

Host:	Mouse (1) Rabbit (3)
Reactivity:	Human (4)
Application:	IHC-P (3) ICC/IF (2) IP (1) WB (3) FC (2)
Isotype:	IgG (3) IgG1 (1)
Conjugation:	Non-conjugated (4) Biotin (96)
Clonality:	Monoclonal (3) Recombinant (3)
Modification:	Unmodified (3)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83577

	MHC Class I Antibody (YA3322) Aw-68; HLA class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; HLA-A; MHC class I antigen HLA* A heavy chain	WB, IHC-P	Human
	MHC Class I Antibody (YA3322) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MHC Class I.

HY-P83577A

	MHC Class I Antibody (YA3322)(PBS only) Aw-68; HLA class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; HLA-A; MHC class I antigen HLA* A heavy chain	WB, IHC-P	Human
	MHC Class I Antibody (YA3322) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to MHC Class I.

HY-P83195

	HLA Class 1 A Antibody (YA2940) Aw-68; HLA class I histocompatibility antigen; A-28 alpha chain; MHC class I antigen A68; HLA-A; MHC class I antigen HLA* A heavy chain	WB, IHC-P, ICC/IF, IP, FC	Human
	HLA Class 1 A Antibody (YA2940) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to HLA Class 1 A.

HY-P84941

	HLA Class 1 ABC Antibody (YA4638) Antigen Presenting Molecule antibody; Cw1701 antibody; D6S204 antibody; FLJ27082 antibody; HLA* A antibody; HLA B antibody; HLA C antibody; HLA class 1 A antibody; HLA class 1 B antibody; HLA class 1 C antibody; HLA JY3 antibody; HLAA antibody; HLAB antibody; HLAC antibody; HLC C antibody; Human Leucocyte Antigen C antibody; Major Histocompatibility Complex Class I A antibody; Major Histocompatibility Complex Class I B antibody; Major Histocompatibility Complex Class I C antibody; Major histocompatibility complex, class I, A + B + C antibody; MHC class I antigen A1 antibody; MHC Class I Antigen antibody; MHC class I antigen B7 antibody; MHC class I antigen Cw1 antibody; MHC class I HLA* A antibody; MHC class I HLA B antibody; MHC class I HLA C antibody; MHC HLA ABC antibody; PSORS1 antibody	ICC/IF, FC	Human
	HLA Class 1 ABC Antibody (YA4638) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to HLA Class 1 ABC.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Human (165) Mouse (5)
Tag:	His (169) Avi (163)
Source:	HEK293 (167) CHO (1) E. coli (1)

HLA-A

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products